BRICS Radiofrequency Ablation Market (2022-2033)

Growing Interest in Minimally Invasive Approaches

BRICS is experiencing increasing interest in minimally invasive procedures, with radiofrequency ablation (RFA) emerging as a preferred option for therapeutic applications, including cardiology, oncology, and chronic pain management. Healthcare providers are increasingly prioritizing procedures that reduce surgical trauma, lower complication risks, and enable quicker recovery. This trend reflects a broader regional focus on modernizing healthcare infrastructure and improving patient-centered care across both public and private sectors.

Major medical centers in urban and metropolitan areas are investing in advanced imaging systems and interventional technologies to facilitate precise RFA procedures. Growing access to trained interventional specialists supports the safe adoption of these minimally invasive approaches. Hospitals and clinics are incorporating RFA into clinical protocols as a reliable alternative to open surgery, reinforcing clinician confidence and encouraging wider patient acceptance.

Patients seek treatments that minimize hospitalization and allow for faster return to daily routines. Rising prevalence of non-communicable and chronic conditions across the region further amplifies demand for minimally invasive solutions, positioning RFA as a critical tool in modern healthcare delivery and expanding its utilization across diverse healthcare settings.

Outpatient Care Growth and Service Expansion

The expansion of outpatient and ambulatory care services is creating opportunities for the RFA market in BRICS. Healthcare systems are focusing on optimizing hospital capacity, improving operational efficiency, and enhancing patient convenience by shifting suitable procedures to outpatient settings. The minimally invasive profile of RFA, combined with short recovery periods, makes it suitable for day-care treatment models, enabling providers to serve more patients efficiently.

Private healthcare networks and specialized surgical centers are increasingly integrating RFA into their outpatient services for cardiac, oncological, and pain-related applications. Evolving reimbursement policies and healthcare financing models in the region are also supporting the adoption of ambulatory procedures. As a result, more patients can access advanced therapies without the need for prolonged hospital stays, while healthcare providers benefit from cost-effective, high-throughput service delivery.

Despite progress, challenges remain in extending outpatient RFA access to less urbanized areas due to infrastructure gaps and limited availability of trained personnel. However, ongoing investments in clinical training, facility upgrades, and workflow optimization are addressing these barriers. As outpatient services continue to expand, the BRICS RFA market is expected to witness steady growth, driven by both increased procedural adoption and enhanced healthcare delivery efficiency.

The "BRICS Radiofrequency Ablation Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• BRICS Radiofrequency Ablation market size and forecast at regional and country levels for segments covered under the scope
• BRICS Radiofrequency Ablation market trends, as well as drivers, restraints, and opportunities
• BRICS Radiofrequency Ablation market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the BRICS Radiofrequency Ablation market
• Detailed company profiles, including SWOT analysis

The geographical scope of the BRICS radiofrequency ablation market report is divided into: Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. China held the largest share in 2025.

China is the dominant market for RFA within the BRICS grouping, driven by its extensive investments in modern healthcare infrastructure and specialist training. Major urban centers serve as hubs for cardiac ablation, interventional oncology, and chronic pain management procedures. Hospitals and academic medical centers are adopting RFA technologies, integrating them into structured treatment protocols that emphasize minimally invasive approaches and improved patient outcomes. The country’s focus on technological innovation, clinical research, and training programs has accelerated procedural expertise among physicians and increased confidence in adopting RFA as a preferred therapeutic option.

Private healthcare institutions and specialized clinics play a pivotal role in promoting early adoption and expanding awareness among clinicians and patients. Strategic collaborations with global device manufacturers support technology transfer, hands-on training, and integration of advanced ablation platforms. Despite these strengths, challenges remain in bridging access disparities between urban hospitals and rural healthcare facilities, where advanced procedural capabilities are limited. Ensuring continued training for specialists and expanding infrastructure beyond metropolitan centers are critical for sustaining China’s leadership in the RFA market within BRICS. The country’s approach reflects a blend of technological adoption, clinical rigor, and strategic infrastructure development that drives regional dominance.

• The report includes qualitative and quantitative data in the BRICS Radiofrequency Ablation market across product type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the BRICS Radiofrequency Ablation market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the BRICS Radiofrequency Ablation market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the BRICS Radiofrequency Ablation market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover the BRICS Radiofrequency Ablation market segments by product type, application, end user, and geography across Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the BRICS Radiofrequency Ablation market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The BRICS radiofrequency ablation market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the BRICS radiofrequency ablation market are:

• In February 2025, Shanghai Golden Leaf Med Tec Co., Ltd. announced that its Radio Frequency Renal Ablation Device and Disposable Reticular Renal Denervation RF Ablation Catheter were approved for marketing by the China National Medical Products Administration (NMPA). This approval covers both the main RF ablation unit and its disposable catheter components, facilitating broader clinical use in China for the adjunctive treatment of refractory and drug‑intolerant hypertension using radiofrequency technology.
• In July 2024, Stryker Corporation announced the launch of its MultiGen 2 Radiofrequency (RF) Generator in India, a next‑generation RF ablation system for chronic joint pain management. This device provides physicians with enhanced control and reliability for RF ablation procedures, supporting minimally invasive treatments in Indian clinical settings and expanding RFA technology availability in the BRICS market.